IMMP - Immutep stock climbs on start of trial of eftilagimod for breast cancer

2023-03-14 09:16:22 ET

• Immutep ( NASDAQ: IMMP ) said it started a phase 2/3 trial of eftilagimod alpha (efti) in combination with paclitaxel to treat metastatic HER2-neg/low breast cancer (MBC).
• The company has received regulatory approval in the U.S. and greenlight from the Institutional Review Board (IRB)  in Spain. Approvals in more countries are expected soon, the company added.
• The first patient is anticipated to be enrolled in early Q2.
• In the study, dubbed AIPAC-003, the HR+/HER2-neg/low MBC patient population has been expanded to include patients with triple-negative breast cancer (TNBC) following feedback from the FDA and the European Medicines Agency (EMA), Immutep noted.
• IMMP +8.43% to $1.80 premarket March 14

For further details see: